INHIBRX BIOSCIENCES, INC. Increase (Decrease) in Other Receivables
INHIBRX BIOSCIENCES, INC. (INBX) reported Increase (Decrease) in Other Receivables of -$45.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other receivables for the quarter ending 2026-06-30 was -$54.00K, a 108.04% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other receivables for the quarter ending 2026-03-31 was $9.00K, a 47.06% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other receivables for the quarter ending 2025-12-31 was -$706.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other receivables for the quarter ending 2025-09-30 was -$3.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other receivables for fiscal 2025 was -$20.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in other receivables for fiscal 2024 was -$566.00K.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 3 month as first filed | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$45.00K 10-Q · filed 2026-08-13 | -$751.00K derived: sum of 3 quarters · filed 2026-08-13 | -$754.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $9.00K 10-Q · filed 2026-05-14 | -$697.00K derived: sum of 2 quarters · filed 2026-05-14 | -$700.00K derived: sum of 3 quarters · filed 2026-05-14 | -$28.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$706.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$709.00K derived: sum of 2 quarters · filed 2026-03-19 | -$37.00K derived: sum of 3 quarters · filed 2026-08-13 | -$20.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $669.00K derived: sum of 2 quarters · filed 2026-08-13 | $686.00K 10-Q · filed 2025-11-14 | $543.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $672.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $689.00K 10-Q · filed 2026-08-13 | $546.00K derived: sum of 3 quarters · filed 2026-08-13 | -$222.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $17.00K 10-Q · filed 2026-05-14 | $0.00 10-Q · filed 2025-05-14 | -$126.00K derived: sum of 2 quarters · filed 2026-05-14 | -$894.00K derived: sum of 3 quarters · filed 2026-05-14 | -$1.16M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$911.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.18M derived: sum of 3 quarters · filed 2026-03-19 | -$566.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$768.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.03M derived: sum of 2 quarters · filed 2025-11-14 | -$423.00K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $345.00K 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $610.00K 10-Q · filed 2025-05-14 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |